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ABSTRACT  
Objective: To study the Fate of Hepatitis C patients on 
antiviral therapy.  
Place and Duration of Study: This study was carried 
out from March 2018 to Oct 2018 at Mayo Hospital, 
Lahore.  
Materials and Methods: In this study 200 hepatitis C 
patients on antiviral therapy were included. Kit method 
was used for diagnosing hepatitis C in all the patients and 
thereafter before initiating antiviral therapy it was 
confirmed by quantitative PCR. Before the initiation of 
antiviral therapy, quantitative PCR, Liver Function Test, 
blood picture was calculated. In order to see the exact 
liver picture, the abdominal ultra sound was performed. 
All the Hepatitis C patients of this study had the 
following antiviral therapy. 1 Sofsububir 400mg (OD), 2. 
Daclatasvir 60mg (OD), 3. Rivavirin 400mg (TDS). 
After the completion of the therapy, these tests were 
performed again. In order to record age, sex and above 
tests, a Performa was designed. From all the participants 
of the research an informed written consent was 
obtained. Before collection and publish of data, the 
permission was sought from the ethical committee of the 
institution. SPSS version 10 was used for analysing the 
results.  
Results: The hepatitis C frequency was found maximum 
35 (17.5%), 13% male and 22% female between the age 
group of 41 to 50 years and was found minimum 7(3.5%) 
1% female and 2.5% male between the age group of 61 
years and above.  
Relating to the antiviral therapy complications it was 
found that in 9% patients of hepatitis C the acities was 
seen, in 19% patients anaemia was seen, in 2% patients 
Hepatic Encephalopathy was seen and in 1% patients 
Liver Cirrhosis was seen . 
When the therapy was finished 182(91%), were cured 
whereas 18 hepatitis C patients could not be cured.  
Conclusion:The conclusion was drawn on follow up that 
in hepatitis C patients there were complications (Acities, 
Hepatic Encephalopathy, Anaemia, Cirrhosis etc.) even 
after the treatment of antiviral therapy 
Key Words:Antiviral Therapy, Fate, Hepatitis C, 
PCR. 
INTRODUCTION  
Hepatitis C is main public health issue. Hepatitis C 
is the key cause for the chronic liver disease and 
sole most frequent sign for the liver transplantation 
among the 4 million Americans having the chronic 
infection(Asselah, Perumalswami, & Dieterich, 
2014). Antiviral therapy is found effective in more 
than 50% of the patients infected whereas the real 
sustained rate of viral response depends on host, 
viral, and adherence elements(Akuta, Suzuki, 
Hirakawa, Kawamura, Sezaki, & Suzuki, 2011). 
Host and viral elements have no tendency for the 
modification, but adherence may be increased by 
interventions. However, adherence treatment is 
directly affected by the adverse effect from 
antiviral therapy and can reduce the probability of a 
sustained viral response(Foster, 2009).  
The quality of life can hardly be compromised with 
these complications. Mostly HCC patients have 
underlying chronic liver disease, mainly resulting 
from chronic infections by hepatitis C virus (HCV), 
hepatitis B virus (HBV), consumption of alcohol 
excessively and sometimes on the connection of 
these cause. Due to the increasing incidence in the 
industrialised countries, HCC is gaining more 
interest(Liang & Heller, 2006). HepatoCellur 
Carcinoma (HCC) is the most fast enhancing 
reason for death due to cancer with HCV as the 
main aetiology generally affecting more than 50% 
of patients with HCC in developed countries like 
America(Backus, Boothroyd, Phillips, Belperio, 
Halloran, & Mole, 2011). The urgent need for 
identification of undiagnosed HCV infection has 
been highlighted by these researches by way of 
implementing HCV screening programs aiming 
populations with high risk and better access to new 
generation anti HCV therapies with decreased cost 
with effective treatment and follow-up(Fried, 
2002). Retrospective questioning to the earlier 
treated patients mainly by interferon-based 
regimens have shown numerous post SVR HCC 
connected clinical variable, mostly are the 
identified HCC risk elements in patients having 
active GCV infection. Extra advanced liver fibrosis 
and biochemical or imaging substitute of 
histological fibrosis (for example serum albumin, 
fibrosis-4 index, platelet count, elastography-based 
lover stiffness, aspartate aminotransferase-to-
platelet ratio index) before or/and after the 
treatment of antiviral are the most common 
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elements connected with high post SVR HCC risk. 
The object of the basic prevention is to delay or 
avoid the prevalence of HCC with the use of 
medical treatments(Lavanchy, 2008).  
MATERIALS AND METHODS  
In this prospective study, 200 hepatitis C patients 
on antiviral therapy were included.Kit method was 
used for diagnosing hepatitis C in all the patients 
and thereafter before initiating antiviral therapy it 
was confirmed by quantitative PCR. Before the 
initiation of antiviral therapy, quantitative PCR, 
Liver Function Test, blood picture was calculated. 
In order to see the exact liver picture, the 
abdominal ultra sound was performed. All the 
Hepatitis C patients of this study had the following 
antiviral therapy.  
1. Sofsububir 400mg (OD) 
2. Daclatasvir 60mg (OD) 
3. Rivavirin 400mg (TDS). 
After the completion of the therapy, these tests 
were performed again. In order to record age, sex 
and above tests, a Performa was designed. From all 
the participants of the research an informed written 
consent was obtained. Before collection and 
publish of data, the permission was sought from the 
ethical committee of the institution. SPSS version 
10 was used for analysing the results. 
RESULTS  
The hepatitis C frequency was found maximum 35 
(17.5%), 13% male and 22% female between the 
age group of 41 to 50 years and was found 
minimum 7(3.5%) 1% female and 2.5% male 
between the age group of 61 years and above 
(Table 1).  
Table 1: Gender and age distribution 
Age groups Males Females 
20-30 9 (4.5%) 13 (6.5%) 
31-40 11 (5.5%) 15 (7.5%) 
41-50 13 (6.5%) 22 (11%) 
51-60 12 (6%) 11 (5.5%) 
61 and above 5 (2.5%) 2 (1%) 
Total 100 (50%) 100 (50%) 
Relating to the antiviral therapy complications it 
was found that in 9% patients of hepatitis C the 
acities was seen, in 19% patients anaemia was 
seen, in 2% patients Hepatic Encephalopathy was 
seen and in 1% patients Liver Cirrhosis was seen . 
When the therapy was finished 182(91%), were 
cured whereas 18 hepatitis C patients could not be 
cured.  
DISCUSSION  
In the middle of 2011, HCV infection treatment 
was revolutionised by including Direct acting 
Antiviral Agents (DAAs) - the protease blockers 
boceprevir (Vic-trelis, Merck) and telaprevir 
(Incivek, Vertex) – to the ten years long period 
standard of care (SOC) therapy of pegylated 
interferon α-2a/b and ribavirin. This advancement 
resulted in marvellous need for HCV therapy, 
taking to supply of rationing and treatment triage. 
The idea of distributive justice with limited supply 
proposes that there is an urgent need of treatment 
for the patients having cirrhosis and therefore the 
treatment should be given on top priority basis, 
with asymptomatic patients having nominal fibrosis 
being at the other end of spectrum. Early 
experience with DAAs therapy shows this urgent 
need: tela-previr was started on the first 98 HCV 
infected patients, mostly 40% had advanced 
cirrhosis or fibrosis. The current review 
investigated the information on the DAAs in 
patients with cirrhosis and explained the 
development of HCV therapy in this special group 
form the standard of care therapy of the early ten 
years into the DAAs new age. Now with the use of 
antiviral agents the hepatitis C has become a 
curable illness (>95%). The side effects of 
hematologic are the most recurrent abnormal 
laboratory value which can result in reduced dose 
and termination of premature treatment. Interferon 
can affect white blood cell, haemoglobin and 
platelet values because of myelosuppressive 
effects.However, during the combination, the 
anaemia has been seen, mostly connected with the 
ribavirin resulting haemolytic anaemia. In the 
current research relating to the antiviral therapy 
complications it was observed that in 9% patients 
of hepatitis C the acities was seen, in 19% patients 
anaemia was seen, in 2% patients Hepatic 
Encephalopathy was seen and in 1% patients Liver 
Cirrhosis was seen 
CONCLUSION  
The conclusion was drawn on follow up that in 
hepatitis C patients there were complications 
(Acities, Hepatic Encephalopathy, Anaemia, 
Cirrhosis etc.) even after the treatment of antiviral 
therapy 
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